CHEMOTHERAPY AND
IMMUNOTHERAPY (2025) EXAM
QUESTIONS AND ANSWERS
Predictors of PDL1/PD1 inhibitor response - Presence of tumor CD8 cell infiltration
High cancer genome burden
High levels of cancer PD-L1 expression
(PD1 is on the cytotoxic T cell)
Ipilimumab - CTLA4 inhibitor
Nivolumab - PD-1 inhibitor
Regorafenib - VEGF inhibitor
Bevacizumab - Monoclonal antibody against VEGF-A. Inhibits angiogenesis.
Pembrolizumab - PD-1 inhibitor
Atezolizumab - PD-L1 inhibitor
Avelumab - PD-L1 inhibitor
Durvalumab - PD-L1 inhibitor
Chemotherapy And Immunotherapy
, Chemotherapy And Immunotherapy
Cemiplimab - PD-1 inhibitor for SCC skin
PARP inhibitors - Inhibit ADP ribosylase
1. Niraparib
2. Olaparib
3. Rucaparib
synthetic lethality with BRCA mutation
Nucleoside analogues - Cytarabine, Fludarabine, gemcitabine
Affect the cell cycle during S
Topoisomerase inhibitors - Etoposide
Doxorubicin- also anthracycline
Teniposide
Irinotecan
Topotecan
Taxanes MOA and examples - inhibit the function of microtubules during M phase
through hyperstabilization
Paclitaxel and docetaxel
Chemotherapy And Immunotherapy